MITRA.BR Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 17:35):

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally...

Stats
Dagens volum	82 336.00
Gjennomsnittsvolum	382 026
Markedsverdi	14.93M
EPS	€0 ( 2024-03-08 )
Neste inntjeningsdato	( €0 ) 2024-05-30
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	-0.150
ATR14	€0.00100 (0.46%)

Mithra Pharmaceuticals SA Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Mithra Pharmaceuticals SA Økonomi

Annual	2023
Omsetning:	€40.16M
Bruttogevinst:	€5.99M (14.92 %)
EPS:	€-2.51

FY	2023
Omsetning:	€40.16M
Bruttogevinst:	€5.99M (14.92 %)
EPS:	€-2.51

FY	2022
Omsetning:	€67.00M
Bruttogevinst:	€35.43M (52.89 %)
EPS:	€-1.220

FY	2021
Omsetning:	€22.67M
Bruttogevinst:	€6.94M (30.63 %)
EPS:	€-1.114

Financial Reports:

No articles found.

Mithra Pharmaceuticals SA

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development candidates include Estelle, which has completed phase III clinical trial, which is a combined oral contraceptive; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a solution for treating menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it offers NEXTSTELLIS, an oral contraceptive pill. In addition, the company provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Liège, Belgium.